<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.02725.003</object-id><label>Table 1.</label><caption><p>Standard diagnostic tests to assess MMR-deficiency</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.02725.003">http://dx.doi.org/10.7554/eLife.02725.003</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Tumor</th><th rowspan="2">Histopathology</th><th rowspan="2">Grade</th><th rowspan="2">Stage</th><th colspan="2">Coverage</th><th align="center" colspan="3">IHC</th><th rowspan="2">MSI</th><th rowspan="2"><italic>MLH1</italic> hyper-methylation</th></tr><tr><th>Tumor</th><th>Germ-line</th><th>MLH1</th><th>MSH2</th><th>MSH6</th></tr></thead><tbody><tr><td>MMR&#8722; 1</td><td>Endometrioid</td><td align="char" char=".">3</td><td>IIIc</td><td align="char" char=".">87.1</td><td align="char" char=".">81.1</td><td>+</td><td>+</td><td>&#8722;(<xref ref-type="table-fn" rid="tblfn1">*</xref>)</td><td>+</td><td>&#8722;</td></tr><tr><td>MMR&#8722; 2</td><td>Serous/clear cell</td><td align="char" char=".">3</td><td>Ib</td><td align="char" char=".">24.8</td><td align="char" char=".">21.9</td><td>+</td><td>&#8722;</td><td>&#8722;</td><td>&#8722;</td><td>&#8722;</td></tr><tr><td>MMR&#8722; 3</td><td>Endometrioid</td><td align="char" char=".">2</td><td>Ib</td><td align="char" char=".">28.5</td><td align="char" char=".">30.0</td><td>&#8722;</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>MMR+ 1</td><td>Endometrioid</td><td align="char" char=".">3</td><td>I</td><td align="char" char=".">119.4</td><td align="char" char=".">73.1</td><td>+</td><td>+</td><td>+</td><td>&#8722;</td><td>+</td></tr><tr><td>MMR+ 2</td><td>Serous</td><td align="char" char=".">3</td><td>Ia</td><td align="char" char=".">79.2</td><td align="char" char=".">77.0</td><td>+</td><td>+</td><td>+</td><td>&#8722;</td><td>&#8722;</td></tr></tbody></table><table-wrap-foot><fn><p>Tumors and matched germ-line were whole-genome sequenced using either Complete Genomics or Illumina sequencing technology. For each tumor, microsatellite instability (MSI) using the extended Bethesda panel, standard immunohistochemistry of MMR proteins (MLH1, MSH2, and MSH6), and methylation status of the <italic>MLH1</italic> promoter are shown.</p></fn><fn id="tblfn1"><label>*</label><p>a weak positive nuclear staining in the minority of the tumor cells.</p></fn></table-wrap-foot></table-wrap>